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vascular stenosis with DEB is associated with signiﬁcantly lower risk
of TLR at both 12 and 24 months. DEB use is also associated with 64%
higher patency rates compared to BA. Further studies are necessary
assess the beneﬁts of mortality with the use of DEB for peripheral
vascular interventions.
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BACKGROUND Implantation of a transcatheter valve into a degen-
erated surgical bioprosthesis during aortic valve-in-valve (ViV) pro-
cedure may signiﬁcantly reduce the effective oriﬁce area (EOA)
available for blood ﬂow. We sought to investigate the impact of
prosthesis-patient mismatch (PPM) on hemodynamics and survival in
these patients.
METHODS A total of 657 data sets of aortic ViV procedures from the
Valve-in-Valve International Data Registry were investigated for the
current analysis. Severe PPM after ViV procedure was deﬁned as an
indexed EOA < 0.65cm2/m2 patient body surface area (BSA).
RESULTS Severe PPM was present in 202 patients after aortic ViV
implantation (30.7% total, 61.4% men, STS score 10.6%). Theincidence of severe PPM was higher in patients who received a
balloon-expandable device than a self-expandable device (38.4% vs.
21.5%, p<0.0001). Patients with severe PPM were younger (77.2  9.4
years vs. 78.7  8.1, p ¼ 0.05) and had larger body weight (80.9  18.9
kg vs. 72.6  14.1, p<0.0001) than those without severe PPM. In
addition, patients with severe PPM had higher aortic mean gradient
after the procedure (21.6  10 mmHg vs. 14.1  7.4) and lower aortic
valve area (1.03  0.2 cm2 vs. 1.66  0.44), in comparison with pa-
tients without severe PPM. Multivariate analysis revealed indepen-
dent predictors for having severe PPM after aortic ViV: effective
oriﬁce area before the procedure (Odds Ratio, OR 0.53 per 1cm2,
conﬁdence interval, CI, 0.3-0.94, p¼0.03), patient age (OR, 0.97 per
1year increment, CI, 0.94-0.99, p¼0.01), using a balloon expandable
device (OR, 2.82, CI, 1.78-4.46, p<0.001). In patients who survived
aortic ViV implantation procedure, one-year survival was not affected
by having severe PPM (93.3% vs. 93.8% in patients without severe
PPM, log rank p¼0.9).
CONCLUSIONS Severe PPM is common after aortic ViV implantation,
occurring in approximately one-third of patients. Predictors for severe
PPM include young age, stenotic surgical valves and balloon-
expandable device implantation. Despite higher valve gradients in
patients with severe PPM, one-year survival was similar to those
without severe PPM. Therefore, the risk of severe PPM should not
discourage operators from performing ViV procedures in inoperable
elderly patients.
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BACKGROUND Cardiac troponin-I (cTnI) is a marker of myocardial
injury and improvements in assay sensitivity allow precise quantiﬁ-
cation at extremely low serum concentrations. Increased cTnI con-
centrations are known to predict outcomes in patients with stable
coronary artery disease, although the underlying mechanisms remain
unknown. As rupture of thin-cap ﬁbroatheroma (TCFA) is thought
responsible for the majority of myocardial infarctions, we tested the
association between baseline cTnI concentration and plaque
classiﬁcation.
METHODS Patients undergoing planned percutaneous coronary
intervention (PCI) for stable angina pectoris (n¼99) underwent 3-
vessel virtual-histology intravascular ultrasound imaging (VH-IVUS,
Eagle-Eye Gold, Volcano Corp) before intervention. Virtual-histology
(VH)-TCFA were deﬁned as plaques (plaque burden >40%) with >10%
necrotic core in contact with lumen for 3 consecutive frames. High-
sensitivity cTnI was taken before PCI (ARCHITECT STAT high-sensi-
tivity cTnI assay, Abbott Laboratories, Abbott Park, Il, USA), with
patients subsequently stratiﬁed into tertiles. Major adverse cardio-
vascular events (MACE) were determined at follow-up (median 1,115
days).
RESULTS Serum cTnI concentrations for each tertile were; low 2.0
[2.0-3.0]ng/L, intermediate 4.0 [4.0-5.0]ng/L and high 7.0 [6.0-18.0]
ng/L. In comparison with the lowest cTnI tertile, highest tertile pa-
tients were older (679.7 vs. 59.810.6yrs, p¼0.002). However, there
were no other differences in demographics between these groups,
including diabetes mellitus (14.8 vs. 12.0%, p¼0.98), hypertension
(55.6 vs. 44.0%, p¼0.33) and serum creatinine (1.000.15 vs.
0.970.21mg/dL, p¼0.37). On 3-vessel VH-IVUS, total plaque number
(p¼0.27), plaque volume (p¼0.09), % necrotic core (p¼0.17) and %
calciﬁcation (p¼0.21) were similar between lowest and highest ter-
tiles. However, patients in the highest cTnI tertile had a higher
number of VH-TCFA, when compared with lowest tertile (2.0 [1.0-2.8]
vs. 1.0 [0.0-1.3], p¼0.027). On multivariable linear regression analysis,
cTnI concentration (p¼0.01) was independently associated with
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on univariate analysis (HR 2.2, 95%CI 1.2-4.0, p¼0.007).
CONCLUSIONS Increased baseline cTnI in patients with stable angina
is associated with the presence of vulnerable plaques and future
MACE. These results suggest a potential mechanism underlying the
prognostic value of cTnI in patients with stable angina.
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BACKGROUND The role of anticoagulants during percutaneous cor-
onary intervention (PCI) in acute coronary syndrome (ACS) is
increasingly important. The CARTAGOMAX study aims to assess the
efﬁcacy and safety of bivalirudin (BIVA) versus unfractionated hepa-
rin (UFH) plus glycoprotein IIb/IIIa inhibitors (GPI) during PCI in the
real world.
METHODS We performed a single-center and prospective study. All
patients with acute coronary syndrome (with and without ST segment
elevation) who underwent percutaneous coronary intervention in our
cardiac catheterization laboratory between January 2010 and
December 2014 were eligible for inclusion. All received loading dose of
aspirin and clopidogrel. Patients were successively anticoagulated
either with BIVA or with UFH plus GPI, in a 2:1 ratio. The main
objective was to compare mortality and major bleeding rates at 1, 6
and 12 months of follow-up. As secondary objectives, the presentation
of stroke, reinfarction and stent thrombosis was analyzed. All patients
signed informed consent. Study protocol was approved by our hos-
pital ethics committee. We performed univariate analysis and binary
logistic regression analysis. Survival analysis was performed using
Kaplan-Meier method using the log rank test, which is expressed
followed by relative risk (RR) with the 95% conﬁdence interval.
RESULTS A total of 1800 patients were included. 31,6% were diag-
nosed with ACS with ST segment elevation and 68,4% with ACS
without ST segment elevation. 1183 (65,7%) of patients received BIVA
and 617 (34,3%) were treated with UNH+GPI. Baseline characteristics
are shown in table 1. No signiﬁcant differences in mortality were
observed between the two groups at 30 days (p¼0,231; RR 0,8-2,2)
and at 6 months follow-up (p¼0,12; RR 0,9-2,1 ). At one year follow-
up, a non-signiﬁcant trend to lower mortality was observed in the
bivalirudin group (p¼0,052; RR1,01-2,15). The incidence of major
bleeding was higher in the arm treated with UNH+GPIat 1 month
(p¼0,001; RR 1,4-40,9), at 6 months (p¼0,009 RR 1,2-5,05) and at 12
months (p¼0,061; RR 0,9-3,3).Similar results were obtained when
the occurrence of cerebral ischemic events was analyzed. The
incidence of stroke ratio was lower in the BIVA arm at 1 month
(p¼0.015; RR 1,4-40,9), at 6 months (p¼0,003; RR 1,6-24,6) and at 1
year (p¼0,032; RR 1,03-7,8). The rates of re-infarction were similar
in both groups. A nonsigniﬁcant trend to higher stent thrombosis in
the BIVA arm was observed.Heparin + IGP Bivalirudin Total p valueAge, years 66,18  12,2 67,14  12,5 66,61  12,49 0,119
Female gender 129 (20,9) 327 (27,7) 456 (25,3) 0,002dyslipidemia 280 (45,4) 620 (53,4) 900 (50) 0,005Hypertension 339 (54,9) 754 (63,7) 1093 (60,7) 0,001Diabetes 211 (34,2) 513 (43,4) 724 (40,2) 0,001Smoking 286 (46,4) 537 (45,4) 823 (45,7) 0,698Radial access 278 (45,2) 723 (61,6) 1001 (56) 0,001LVEF 54,36  11 54,38  11 59,41  14,76 0,971
No diseased
vessels1,73  0,76 1,76  0,81 1,75  0,8 0,527No treated
vessels1,15  0,39 1,24  0,46 1,21  0,44 0,001No implanted
stents1,8  1,06 1,77  1,04 1,78  1,05 0,654GFR, ml/min/
1,73m287,9  44,57 87,7  42,52 87,8  43,17 0,925Platelets, mcL 217610  64750 221380  91120 220200  83773 0,405
Contrast, ml. 340  178,68 286  128,18 305,1  149,53 0,001CONCLUSIONS In the CARTAGOMAX study the use of bivalirudin
during PCI is presented as an effective and safe option, with a lower
rate of major bleeding and stroke, and similar mortality and stent
thrombosis over the use of UFH plus a GPI.
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BACKGROUND Prasugrel and ticagrelor are potent P2Y12 ADP recep-
tor inhibitors that have greater clinical efﬁcacy compared with clopi-
dogrel, but more non-CABG bleeding. There are no direct comparisons
of clinical outcomes between the drugs with follow-up through 1 year.
This retrospective study compared 1 year post discharge outcomes
between the 2 agents in acute coronary syndrome patients (pts)
managed with percutaneous coronary intervention (ACS-PCI) using a
claims database.
METHODS ACS-PCI pts  18 years, with no history of TIA or stroke, a
physician visit 90 days post discharge, and at least 1 outpatient
pharmacy ﬁll 30 days post discharge for prasugrel or ticagrelor, but
not both, were included. Data from the ProMetis Lx database were
propensity matched for prasugrel use with a 3 prasugrel:1 ticagrelor
ratio. Unadjusted clinical outcomes were assessed using descriptive
methods on an as treated basis. Propensity matched clinical outcomes
were compared using Cox proportional hazards models and Kaplan-
Meier analysis. Post discharge net adverse clinical events (NACE) at
1 year was evaluated for non-inferiority of outcomes between the
2 populations using a 20% margin. NACE was a composite of major
adverse cardiovascular events (MACE) or rehospitalization for
bleeding. MACE was the composite of all-cause death, coronary
revascularization, or rehospitalization for MI, unstable angina (UA),
TIA/stroke, or CHF.
RESULTS Of the 173,484 ACS-PCI pts in the database, 15,788 were
included (prasugrel 12,797; ticagrelor 2,991). Compared with ticagrelor
pts, prasugrel pts were younger, less likely to be female, have prior
MI, diabetes, or present with NSTEMI; more likely to have UA; no
signiﬁcant difference in the rate of STEMI. Prior to matching, prasu-
grel pts had lower rates of NACE and MACE (p<0.01), with no differ-
ence in bleeding (Table), compared with ticagrelor pts. After
propensity matching, there was no signiﬁcant difference in baseline
characteristics between the two groups. Non-inferiority was
demonstrated related to outcomes associated with prasugrel use
compared with outcomes associated with ticagrelor use (Table).
Rates of NACE and MACE remained signiﬁcantly lower in the
